I. Atherosclerosis And Cardiovascular Disease.- 1. PPAR-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis.- 2. The Choice of an Appropriate Animal Species in the Study of Chlamydia pneumoniae as an Atherogenic Agent.- 3. Endothelial Cell Dysfunction-A Key Factor in Atherogenesis and its Reversal (Laboratory and Clinical Study).- 4. Biochemical Mechanisms of Hyperhomocysteinemia in Atherosclerosis: Role of Chemokine Expression.- 5. Oxyradicals and Hypercholesterolemic Atherosclerosis.- 6. Identification, Regulation and Function of LOX-1, A Novel Receptor for Ox-LDL.- 7. Atherosclerosis and Angiotensin II in Hypercholesterolemia and Diabetes. A Role for ATt Receptors Beyond Hypertension.- 8. Basic and Clinical Results of New Statin: Pitavastatin.- 9. Reducing Cardiovascular Risk With HMG CoA Reductase Inhibitors, Potential Contribution From Platelets.- 10. Rapamycin-Sensitive Signal Transduction Pathways and the Control of Adipogenesis.- II. Hypertension.- 11. Genetic Predisposition to Hypertension and Cardiovascular Disease.- 12. Role of Sympathetic Nervous System in Hypertension.- 13. Role of Hypothalamic Peptides in the Development of Hypertension.- 14. Myosin Light Chain Kinase in Endothelial Cell Calcium Signaling and Endothelial Functions.- 15. Sarpogrelate Inhibits Genes Involved in Vascular Neointimal Hyperplasia and Remodeling.- 16. A Nutritional Approach to Prevent High Blood Pressure.- 17. Cardiovascular and Renal Actions of Leptin.- 18. Brain Na, K-ATPase Enzymatic Activity and Cardiovascular Regulation.- 19. Development of Transdermal and Transbuccal Drug Delivery Systems for Cardioactive Drugs with Special Reference to Anti-Hypertensive Agents.- 20. Insulin Resistance and Experimental Hypertension.- III. DiabetesMellitus.- 21. New Paradigm for Insulin Resistance: The HISS Story.- 22. Vanadium Effects in Diabetes.- 23. Dyslipoproteinemia and Fibrinolysis.- 24. Endothelins and Cardiovascular Disease in Diabetes.- 25. Usefulness of 5-HT2A Receptor Antagonists for the Treatment of Cardiovascular Complications in Diabetes.- 26. Selective Attenuation of Enhanced Angiotensin II Mediated Responses in the Streptozotocin Diabetic Rat Thoracic Aorta by Tempol.- 27. Role of Renin-Angiotensin System in Diabetic Heart Dysfunction and Changes in Phospholipase C Activity.- 28. Regulation of Cardiac Function in Diabetes.- 29. Diabetes and Cardiac Dysfunction.- 30. Mechanisms Underlying Contractile Dysfunction in Streptozotocin-Induced Type 1 and Type 2 Diabetic Cardiomyopathy.- 31. Protein Kinase C Signaling and Expression of the Diabetic Cardiac Phenotype.- 32. Oxidative Stress in Cardiovascular Complications of Diabetes.- 33. Augmented Energy Transfer in Rat Heart Mitochondria: Compensatory Response to Abnormal Household of Energy in Acute Diabetes.- 34. Ketosis, Tumor Necrosis Factor-a and Cardiovascular Disease in Type-1 Diabetic Patients.- 35. Epigenetic Alterations in Diabetic Cardiomyopathy.
Inhaltsverzeichnis
I. Atherosclerosis And Cardiovascular Disease. - 1. PPAR-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis. - 2. The Choice of an Appropriate Animal Species in the Study of Chlamydia pneumoniae as an Atherogenic Agent. - 3. Endothelial Cell Dysfunction A Key Factor in Atherogenesis and its Reversal (Laboratory and Clinical Study). - 4. Biochemical Mechanisms of Hyperhomocysteinemia in Atherosclerosis: Role of Chemokine Expression. - 5. Oxyradicals and Hypercholesterolemic Atherosclerosis. - 6. Identification, Regulation and Function of LOX-1, A Novel Receptor for Ox-LDL. - 7. Atherosclerosis and Angiotensin II in Hypercholesterolemia and Diabetes. A Role for ATt Receptors Beyond Hypertension. - 8. Basic and Clinical Results of New Statin: Pitavastatin. - 9. Reducing Cardiovascular Risk With HMG CoA Reductase Inhibitors, Potential Contribution From Platelets. - 10. Rapamycin-Sensitive Signal Transduction Pathways and the Control of Adipogenesis. - II. Hypertension. - 11. Genetic Predisposition to Hypertension and Cardiovascular Disease. - 12. Role of Sympathetic Nervous System in Hypertension. - 13. Role of Hypothalamic Peptides in the Development of Hypertension. - 14. Myosin Light Chain Kinase in Endothelial Cell Calcium Signaling and Endothelial Functions. - 15. Sarpogrelate Inhibits Genes Involved in Vascular Neointimal Hyperplasia and Remodeling. - 16. A Nutritional Approach to Prevent High Blood Pressure. - 17. Cardiovascular and Renal Actions of Leptin. - 18. Brain Na, K-ATPase Enzymatic Activity and Cardiovascular Regulation. - 19. Development of Transdermal and Transbuccal Drug Delivery Systems for Cardioactive Drugs with Special Reference to Anti-Hypertensive Agents. - 20. Insulin Resistance and Experimental Hypertension. - III. DiabetesMellitus. - 21. New Paradigm for Insulin Resistance: The HISS Story. - 22. Vanadium Effects in Diabetes. - 23. Dyslipoproteinemia and Fibrinolysis. - 24. Endothelins and Cardiovascular Disease in Diabetes. - 25. Usefulness of 5-HT2A Receptor Antagonists for the Treatment of Cardiovascular Complications in Diabetes. - 26. Selective Attenuation of Enhanced Angiotensin II Mediated Responses in the Streptozotocin Diabetic Rat Thoracic Aorta by Tempol. - 27. Role of Renin-Angiotensin System in Diabetic Heart Dysfunction and Changes in Phospholipase C Activity. - 28. Regulation of Cardiac Function in Diabetes. - 29. Diabetes and Cardiac Dysfunction. - 30. Mechanisms Underlying Contractile Dysfunction in Streptozotocin-Induced Type 1 and Type 2 Diabetic Cardiomyopathy. - 31. Protein Kinase C Signaling and Expression of the Diabetic Cardiac Phenotype. - 32. Oxidative Stress in Cardiovascular Complications of Diabetes. - 33. Augmented Energy Transfer in Rat Heart Mitochondria: Compensatory Response to Abnormal Household of Energy in Acute Diabetes. - 34. Ketosis, Tumor Necrosis Factor-a and Cardiovascular Disease in Type-1 Diabetic Patients. - 35. Epigenetic Alterations in Diabetic Cardiomyopathy.
